Opthea Limited Sponsored ADR (OPT) has released an update.
Opthea Limited, a biopharmaceutical company focused on innovative therapies for retinal diseases, will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024. Their lead product candidate, sozinibercept, is currently in two pivotal Phase 3 clinical trials aimed at improving treatment outcomes for wet age-related macular degeneration. The event will feature a presentation by CEO Frederic Guerard and offer investor meetings to discuss the company’s advancements.
For further insights into OPT stock, check out TipRanks’ Stock Analysis page.
